JOANNA GULLION: Open Payments
NPI 1669142477 · LEXINGTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,853 in 90 payments from 25 companies in 2025. Trend: 2023 $22 · 2024 $0 · 2025 $1,853
Food & beverage: $1,853
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $332 |
| ABBVIE INC. | 19 | $292 |
| Alkermes, Inc. | 14 | $248 |
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $154 |
| Vanda Pharmaceuticals Inc. | 2 | $151 |
| GlaxoSmithKline, LLC. | 5 | $96 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Astellas Pharma US Inc | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $45 |
Products named: BREZTRI, LYBALVI, VRAYLAR, Kerendia, FANAPT, TRELEGY ELLIPTA, CAPLYTA, Veozah.
Industry payments across IN — which companies pay providers there.
